Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs
Status:
Terminated
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
This study is a phase IV, open-label, single arm, multicentre study whose aim is to assess
whether interferon-free and ribavirin-free Direct Acting Antiviral (DAA) Hepatitis C Virus
(HCV) therapy with grazoprevir/elbasvir, will be feasible for the treatment of People who
inject drugs (PWID) with recent injecting drug use or people receiving opioid substitution
therapy and chronic HCV genotype 1 or 4 infection.